Bajaj Healthcare on Friday said it has received approval from the Gujarat Food and Drug Administration for manufacturing hydroxychloroquine sulphate active pharmaceutical ingredient (API) and formulations, The Economic Times reported on Friday.
"With our existing capabilities and our ability to fast-track production of hydroxychloroquine sulphate and its tablets, we are well-positioned to partially meet the prospective demand," said Bajaj Healthcare CMD Sajankumar Bajaj.
The company will start production of hydhroxychloroquine sulphate API in the next three weeks at its Vadodara facility.
India manufactures 70% of the world's supply of hydroxychloroquine sulphate, the company added.
To read more NewsPoints articles, click here.